Safety and immunogenicity of DNA omicron booster Alveavax-v1.2 in Ad26.COV2.S-vaccinated adults
A phase I study assessed the safety and immunogenicity of the naked DNA Omicron BA.2 booster vaccine, Alveavax-v1.2, in 130 South African adults previously vaccinated with Janssen Ad26.COV2.S. Participants received varying doses intradermally or subcutaneously, or a Janssen booster as a control. The vaccine was well tolerated, with mild to moderate adverse events across all groups and no serious events linked to vaccination. However, the antibody response was modest, with no significant increases in Omicron BA.2 titers observed in any group. The vaccine remained shelf stable for over six months at room temperature.
Authors
- Penny L. Moore (ORCID: https://orcid.org/0000-0001-8719-4028)
- Miti Saksena (ORCID: https://orcid.org/0000-0002-0678-020X)
- Veronique de Jager (ORCID: https://orcid.org/0000-0001-6389-5575)
- Maximilian Schons (ORCID: https://orcid.org/0000-0002-4317-3484)
- Ethan Alley
- Grigory Khimulya
- Vaughan Reed (ORCID: https://orcid.org/0000-0001-6552-1710)
- Carol Crowther (ORCID: https://orcid.org/0000-0002-0287-7004)
- Tobias Odendahl (ORCID: https://orcid.org/0009-0001-5472-6339)
- Zinhle Zwane
- Kgoete Dimakatso
- Phumzile Mhlongo
- James A. Smith (ORCID: https://orcid.org/0009-0002-2736-865X)
- Madeli Kruger
- Anemone Franz
- Kyle Fish
- Sonia Sutherland
Institutions
- University of the Witwatersrand (ZA)
- Amyotrophic Lateral Sclerosis Therapy Development Institute (US)
- Task Applied Science (ZA)
- Cambridge Life Sciences (United Kingdom) (GB)
- Ubuntu Institute (ZA)
- Setshaba Research Centre (ZA)
- Right to Care (ZA)
Publication Details
- Journal
- iScience
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1016/j.isci.2025.113970
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00